NEW YORK (GenomeWeb) – Biocartis announced today that it has submitted its Idylla molecular diagnostics platform to the US Food and Drug Administration for 510(k) clearance, along with a respiratory panel from partner Janssen Diagnostics to detect influenza and respiratory syncytial virus using the Idylla platform.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.